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Abstract 
 
Introduction: Protease activated receptor 2 (PAR2) is self-activated upon cleavage of 
its N-terminus by a proteolytic enzyme, especially a serine protease. PAR2 has been 
implicated in several diseases, including inflammatory, cardiovascular, 
gastrointestinal, respiratory and metabolic diseases as well as in metastatic cancer, 
pain and neurodegenerative conditions, making it an important prospective drug 
target. There are no known endogenous ligands for PAR2, so the availability of potent 
exogenous agonists and antagonists can be helpful for studying physiological 
functions of PAR2, determining its importance in diseases, and as leads to new 
pharmaceuticals. 
  
Areas covered: This review covers agonist-, antagonist-, antibody- and pepducin- 
based modulators of PAR2 reported in patent applications between 2010–2015, along 
with their available structure-activity relationships, biological activities and potential 
uses for studying PAR2. 
 
Expert opinion: In the last six years, substantial efforts have been made towards 
developing PAR2 modulators, but most still lack potency or selectivity or have poor 
pharmacokinetic profiles. The majority of the reported PAR2 modulators were 
assessed by measuring Gαq protein-mediated calcium release in cells. This may be 
insufficient to fully characterize ligand function, since emerging evidence has 
indicated that different ligands signal through PAR2 to different G-protein dependent 
and independent signaling pathways. PAR2 pathophysiology seems linked to specific 
signaling cascades that are differentially affected by different proteases or small 
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molecule agonists or antagonists. Therefore, it may be feasible to develop biased 
ligands as drugs that can selectively modulate one or more specific signaling 
pathways linking PAR2 to a specific diseased state or physiological process, without 
limiting beneficial or protective PAR2 signaling. Accordingly, potent, orally 
bioavailable, pathway- and receptor-selective PAR2 modulators may be an achievable 
goal to realizing effective drugs that can treat PAR2-mediated diseases.  
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1. Introduction 
 
Protease activated receptors (PARs) belong to a unique family of G protein-coupled 
receptors (GPCRs) whose members are not activated by an endogenous ligand. 
Instead, the N-terminus of PARs is cleaved by proteases at a specific site and the 
newly formed N-terminus, known as tethered ligand (TL), then binds elsewhere on 
the receptor to initiate receptor activation [1-3]. There are four subtypes of PARs, 
PAR1, 2, 3 and 4, but only PAR2 is not activated by thrombin. The structure of PARs 
is similar to other GPCRs, consisting of an extracellular N-terminus, an intracellular 
C-terminus, seven transmembrane helices connected by three extracellular and three 
intracellular loops, and a small helix within the intracellular C-terminus. PAR1 and 
PAR3, but not PAR2, contain a negatively charged hirudin-like region on the N-
terminus that binds to the exosite I of thrombin. PAR4, which does not contain a 
hirudin-like region, interacts with the active site of thrombin [4].  
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The N-terminus of PAR2 can be cleaved by proteases, such as trypsin, tryptase, factor 
Xa/VIIa, matriptase, granzyme A, kallikreins (KLK 2/4/5/6/14), MMP-1, cathepsin S, 
elastase, acrosin, HAT, TMPRSS2, chitinase, bacterial gingipains, Der P1–3, Pen C 
13 and testisin to initiate PAR2 activation [2, 5]. These enzymes are not considered to 
be endogenous agonists for PAR2 since they are not bound directly to the activated 
receptor. No endogenous agonists have been reported yet for PAR2. PAR2 is 
primarily cleaved at the canonical site (R36S37) by serine proteases, such as by trypsin, 
tryptase, factor VIIa, matriptase and others [5]. However, it also can be cleaved by 
other proteases (e.g. elastase, cathepsin S) at a different site, either inactivating 
(‘disarming’) PAR2 or producing different TLs [2, 6-9] that initiate different signaling 
profiles, resulting in the phenomenon of biased agonism [10, 11]. PAR2 couples to G 
proteins Gαq, Gαi, Gαs, Gα12/13 and also β-arrestins 1 and 2 to induce downstream 
signaling [12]. Gαq activates production of inositol triphosphate and diacylglycerol, 
resulting in downstream activation of protein kinase C and mobilization of calcium 
ions [13]. The Gαi pathway predominantly inhibits cAMP via inhibition of adenylyl 
cyclase while also activating the mitogen-activated protein kinase (MAPK) pathways. 
In contrast, the Gαs pathway activates adenylyl cyclase, which stimulates cAMP 
production. The Gα12/13 pathway activates the c-Jun N-terminus kinases (JNK) and 
RhoA leading to migration, differentiation and growth [14]. Activation of distinct 
signaling pathways via G proteins or β-arrestins can be associated with different 
diseased states [10, 15]. Activation of PAR2 by agonists or proteases has been shown 
to trigger multiple signaling pathways such as intracellular calcium (iCa2+), MAPK 
and phosphorylation of extracellular signal-regulated kinases (ERK1/2), cAMP, Rho 
kinase, and nuclear factor	kB (NF-kB) pathways [15-17].  
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PAR2 is expressed on numerous epithelial and endothelial cells, including of the lung, 
gastrointestinal tract, skin, kidney, pancreas, liver, heart, smooth muscle cells, 
fibroblasts, nerves and immune and inflammatory cells (T-cells, monocytes, 
macrophages, neutrophils, mast cells and eosinophils) [18-21]. Therefore, it is not 
surprising that PAR2 has roles in physiological processes associated with respiratory 
and gastrointestinal functions, tissue metabolism, immunity and neuronal signaling. 
Monocytes are known to express functional PAR2 and activation of the receptor led 
to the secretion of inflammatory cytokines IL6, IL8 and IL1β [22, 23]. Activation of 
PAR2 on macrophages up-regulates CCL2 and expression of other cytokines [22, 24]. 
PAR2 is widely expressed on astrocytes, microglia and neurons, and studies have 
shown PAR2 to be implicated in neuroinflammation and neurodegeneration [25, 26]. 
On the other hand, PAR2 has been reported to be neuroprotective in ischemic injury, 
infection and Alzheimer’s disease [27-29]. PAR2 is also expressed throughout the 
gastrointestinal tract and mediates salivary, gastric and pancreatic exocrine secretion 
[30]. PAR2 stimulation has been reported to be protective in certain models of acute 
pancreatitis, with PAR2 deficient mice exhibiting more severe pancreatic oedema, 
acinar cell injury and pancreatic inflammation [31-33]. Evidence from PAR2 gene 
deletion in mice, PAR2 expression, PAR2 activation and in some cases PAR2 
antibodies, links PAR2 to either detrimental or beneficial effects in different tissues or 
different disease settings.  
 
Since the discovery of PAR2, a great deal of basic research has been conducted 
towards developing potent PAR2-selective ligands. In the last few years, researchers 
have become more focused on understanding biased pathway- and receptor-selective 
ligands for PARs. This review focuses on PAR2 ligands, antibodies and pepducins 
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reported in patent applications between 2010–2015 and their potential therapeutic 
uses related to PAR2 modulation.  
 
2. PAR2 signaling and disease  	
Activation of PAR2 by proteases or a synthetic agonist is thought to involve 
formation of multiple, as yet undefined, distinct receptor conformations that can elicit 
unique downstream signaling events. These signaling events can be canonical G 
protein-mediated responses such as Gαq-mediated calcium mobilization or G protein-
independent β-arrestin-ERK1/2 phosphorylation. Studies have identified certain 
PAR2 ligands as being biased, being functionally selective through specific signaling 
pathways [2, 10]. Our previous work has demonstrated a PAR2 ligand that selectively 
inhibits Gαq-calcium-PKC signaling and in vivo inflammatory responses, while acting 
as an agonist in activating ERK and Rho pathways [15]. PAR2 activation and 
upregulation has been associated with a number of pathophysiological conditions, 
such as metabolic dysfunction, arthritis, multiple sclerosis and cancers (Table 1). 
PAR2 also plays important roles in modulating inflammatory [19, 34, 35], 
gastrointestinal [36, 37], cardiovascular [38, 39], respiratory [40-42], and metabolic 
diseases [43-45], asthma [41, 46] and cancers [47-49].  
 
However, in certain settings and diseased states, PAR2 activation exerts protective 
effects. Activation of PAR2 has been shown to prevent histamine-induced 
bronchoconstriction [50], ischemia/reperfusion injury [51], colitis [52] and to be 
important in wound healing [53, 54]. Thus, PAR2 may be protective and beneficial, or 
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damaging and detrimental, depending upon the tissue type, the PAR2 ligands used 
and their distribution properties, and the presence of other environmental stimuli.  
 
3. PAR2 peptidic and small molecule agonists 
 
Synthetic PAR2 agonist peptides mimicking the canonical TL sequences (SLIGRL, 
rodent; SLIGKV, human) and ending with a C-terminal amide have been used heavily 
to study the pathophysiology of PAR2. The C-terminal amide is more important for 
agonist potency compared to the N-terminal amine. The rodent hexapeptide 
(SLIGRL-NH2) was 2-fold more potent than the human analogue (SLIGKV-NH2) in 
most cell-based assays [75-77]. However, these six-residue peptides are not very 
potent, high concentrations of these peptides were needed to cause agonist effects. 
Structure-activity relationship (SAR) studies revealed that the agonist activity of 
SLIGRL-NH2 was improved by 10–20 fold when the N-terminal serine (position 1) 
was replaced by a 2-furoyl group (abbreviated as 2f) [78] or other heterocycles [79]. 
The adjacent leucine residue at position 2 was crucial for PAR2 selectivity. Replacing 
it with phenylalanine, 4-fluorophenylalanine in particular, resulted in PAR1 activation 
[77]. Position 3 favored isoleucine or other groups of similar size. The fourth residue, 
glycine, could be replaced with other amino acids without significant loss in potency. 
Positively charged residues were preferred at the fifth position, but hydrophobic 
amino acids were also tolerated. The sixth residue, leucine, was the least important, as 
substitution by many other amino acids did not show significant change in agonist 
potency [77, 79]. However agonist potency was improved when leucine was 
substituted with tyrosine, 4-nitrophenylalanine or 3,4-dichlorophenylalanine [79]. 
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One of the most commonly used PAR2 peptide agonists is 2f-LIGRLO-NH2. This 
peptide activated PAR2 with EC50 0.2 μM in a calcium mobilization assay on HT29 
cells and similar effects vs. several other cell types [78, 80]. Peptides tend to be 
proteolytically cleaved by proteases, making them highly unstable in vivo and they 
have low oral bioavailability in part due to their poor membrane permeation and rapid 
clearance from blood. A patent from Peptron Inc reported 2f-LIGRLO-NH2 
derivatives with N-alkyl amino acids incorporated improved agonist potency and 
proteolytic stability of PAR2 peptides [81]. It is known that N-alkyl amino acids on 
peptides improve biological stability and lipophilicity [82]. The most potent PAR2 
agonist reported in this patent was peptoid 2 containing an isopropyl side chain on the 
amide nitrogen (Figure 1). Peptoid 2 (EC50 42 nM) was ~3-fold more potent than 1 
(EC50 120 nM) when assessed in an intracellular calcium mobilization assay on HCT-
15 human colorectal adenocarcinoma cells. It also displayed longer plasma stability 
than 1, remaining intact in plasma over 48 h whereas peptide 1 was completely 
degraded. There are other PAR2 agonists (3–6, Figure 1) [80, 83-86] that are not 
reported in patents and are therefore not discussed in this review. AY77 (5) was 
reported in a patent [87] and it is a small agonist that activated PAR2-induced calcium 
release with EC50 33 nM in human PAR2 (hPAR2) transfected Chinese hamster ovary 
(CHO) cells [86]. Synthetic agonists are particularly useful for studying the functions 
of PAR2, since no endogenous agonist is yet known for this receptor, and may relieve 
airways inflammation according to reports [40, 41, 46].  
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Figure 1. PAR2 peptidic and non-peptidic agonists 1–6.  
 
4. PAR2 antagonists   
 
The functional properties of PAR2 activation have been investigated extensively by 
PAR2 KO studies (Table 1), indicating that inhibition of PAR2-mediated functions 
could have potential therapeutic applications in multiple human diseases, including 
arthritis, obesity, cardiovascular diseases, brain disorders, cancers and other 
inflammatory diseases such as colitis, inflammatory bowel disease (IBD), dermatitis 
and pancreatitis [2]. Therefore, potent and selective PAR2 antagonists could be 
potential drugs to treat these or related conditions. Antagonists of PAR2 reported to 
date include peptides, small molecules, antibodies and pepducins. In this review, the 
biological properties of PAR2 antagonists, mainly small molecules, as reported in 
patent applications (2010–2015) are briefly summarized.  
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4.1 Peptide antagonists 
 
The first reported PAR2 peptide antagonists were FSLLRY-NH2 and LSIGRL-NH2, 
which inhibited (IC50 50–200 μM) trypsin-induced calcium release in KNRK-PAR2 
cells [88]. Addition of two charged residues (arginine) at the N-terminus of FSLLRY-
NH2, to give RRFSLLRY-NH2, was reported to slightly improve antagonist potency 
[89]. The patent reporting this peptide showed that it had skin-lightening effects and 
might be incorporated into skin care products or used to treat inflammatory skin 
diseases [89].  
 
Another group of PAR2 peptide antagonists was reported for the possible treatment of 
skin diseases, as well as pain. These peptides contained six L-amino acid residues 
capped by an acetyl group at the N-terminus and an amide at the C-terminus. They 
showed 50–90% inhibition of calcium release induced by 2f-LIGRL-NH2 at 1mg/mL 
in human keratinocytes. For example, one of the peptide antagonists Ac-FFWFHV-
NH2 reported in this patent inhibited calcium release and also reduced the release of 
calcitonin gene-related peptide (CGRP) by 80% at 0.5 mg/mL. The PAR2-mediated 
release of CGRP was induced by sensitization of TRPV1. At the same peptide 
concentration (0.5 mg/mL), Ac-FFWFHV-NH2 also inhibited IL-6 production. 
Moreover, this peptide induced proliferation of human keratinocytes by 23% at 25 
μg/mL, suggesting that it might be able to improve the barrier function of skin. 
Additionally, it promoted healing of human keratinocytes by 45% at 0.5 mg/mL and it 
was photo-protective in human dermal fibroblasts at 0.01 μg/mL. This peptide also 
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improved skin hydration in vivo and reduced IL-8 production when induced by 
cosmetic allergens, such as cinnamal and farnesol [90].  
 
Synthetic peptides mimicking the PAR2 cytoplasmic C-terminus have been reported 
to have a possible application in treating cancer [91]. Upon PAR2 activation, the C-
terminus of PAR2 binds to downstream signaling pleckstrin-homology (PH) domain 
containing proteins such as Etk/Bmx. The C-terminus sequence of PAR2 that 
interacts with the PH domain is SHDFRDHA. Therefore, peptides containing this 
sequence (minimum 8 amino acids in length) can interfere the interaction of the PAR2 
C-terminus with PH-domain containing proteins and thus inhibit the associated 
signaling events. These peptides were able to penetrate the cell membrane and were 
suggested to be beneficial for cancer treatment [91]. 
 
4.2 Small molecule antagonists   
 
In the past few years, there has been growing interest in developing small molecule 
antagonists for PAR2, since they are usually more stable in vivo than peptides and 
possess better pharmacokinetic profiles including greater membrane permeability and 
oral bioavailability. Only a few small molecule PAR2 antagonists were reported 
before 2016 in scientific journals (7–15, Figure 2), but most only inhibit PAR2-
induced functions at micromolar/millimolar concentrations when applied to various 
cell lines (e.g. HT29, NCTC2544-PAR2, A549) [80, 92-98]. Some of these antagonists 
also showed biased signaling by selectively inhibiting one signaling pathway but not 
others [15, 96, 99].  
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Figure 2. PAR2 antagonists reported in scientific journals. 
 
Multiple patents published between 2010–2015 have reported small molecule PAR2 
antagonists, with molecular weights (MW) ranging between 200–600 Da (Table 2). 
They were mainly examined in vitro for inhibition of calcium release induced by 
known PAR2 agonists in various cultured human cell types, but few have been shown 
to act specifically on PAR2 or to inhibit key protease, peptide and nonpeptide 
agonists of PAR2. Some of these antagonist compounds were shown to elicit 
responses in rodent models of disease. It is important to point out, however, that not 
all disease models are associated specifically with PAR2 activation, thus in vivo 
effects are not necessarily linked to PAR2 modulation. This should be taken into 
account when interpreting in vitro and in vivo data. All PAR2 antagonists listed in 
Table 2 will be discussed in detail later.  
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4.2.1 Piperazine and piperidine derivatives 
 
Some piperazine derivatives similar to 7 (ENMD-1068) were reported by NeoPharm 
in 2010, with 16 (Figure 3) being the most potent compound reported in the patent. 
This compound (2.5 mM) showed complete inhibition of calcium release induced by 
SLIGKV (2.5 μM) in HCT-15 colon carcinoma cells, a PAR2-overexpressing cell 
line, and was claimed to be useful for treating atopic dermatitis [100]. Compounds 7 
and 16 lacked potency and are likely to have off-target effects at the millimolar 
concentrations required for efficacy.  
 
In 2012, a number of substituted piperidine/piperazine urea derivatives (Figure 3) 
were reported as low micromolar PAR2 antagonists for the inhibition of calcium 
release against trypsin (EC50 concentration) in human PAR2 transfected 1321N1 cells 
[101]. Compounds 17–20 were claimed to show inhibition at or below 5 μM 
concentrations, but the IC50 values were not reported. 
 
Figure 3. Piperazine and piperidine derivatives reported as PAR2 antagonists.  
 
4.2.2 Quinazoline derivatives 
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In 2011, Neopharm reported some quinazoline derivatives as micromolar PAR2 
antagonists (Figure 4). The compound potencies were assessed under the same 
conditions reported in the previous patent, where IC50 was measured as inhibition of 
calcium release induced by SLIGKV (2.5 μM) on HCT-15 cells. This patent 
highlighted four compounds (21–24) with 21 containing a p-fluorophenyl group and 
inhibiting PAR2 with IC50 34 μM. Substituting this group with a thiophene (22, IC50 
17 μM) or cyclopropyl group (23, IC50 15 μM) improved antagonist potency by 2-
fold. Replacing the bromine on the other phenyl ring with chlorine (24) gave a further 
2-fold improvement (IC50 8.6 μM). This patent claimed that these antagonists could be 
useful for the treatment of cardiovascular, gastrointestinal, digestive tract diseases, 
cirrhosis, atopic dermatitis, asthma, etc [102]. Oral bioavailability and 
pharmacokinetic profiles of these quinazoline compounds were not reported in the 
patent, nor was there any data on direct binding or specificity for PAR2. 	 
4.2.3 Benzoimidazole derivatives 
 
NeoPharm also reported a series of benzoimidazole derivatives (25–27, Figure 4) in 
2012 with inhibition at high micromolar concentrations in the same calcium release 
assay on HCT-15 cells. These compounds attenuated the calcium response induced by 
SLIGKV (2.5 μM) with IC50 243, 75 and 77 μM, respectively. They also inhibited β-
arrestin recruitment induced by SLIGKV (10 μM) with IC50 95, 339 and 401 μM, 
respectively. It was noted that these compounds were biased to one particular pathway 
(calcium or β-arrestin), with 25 being more potent in inhibiting the β-arrestin 
recruitment, while 26 and 27 were more effective in antagonizing Ca2+ release. 
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Compounds 25 and 26 have been shown to decrease epidermal thickness, PCNA 
positive keratinocytes, reduce skin barrier disruption and promote skin recovery on an 
oxazolone-induced chronic dermatitis mice model, indicating possible development 
into an anti-inflammatory agent to treat skin diseases [103].  
 
Figure 4. Quinazoline and benzoimidazole derivatives as PAR2 antagonists reported 
by NeoPharm Co. Ltd. from 2011–2012. 
 
4.2.4 Amidine derivatives 
 
Further SAR studies on the piperidine/piperazine urea derivatives (17–20) revealed a 
group of amidine compounds 28–33 (Figure 5). The piperidine/piperazine motif was 
replaced with an aromatic ring and the antagonist potency was improved. These 
compounds were evaluated in the same assay as for 17–20 reported previously, but rat 
or mouse PAR2 transfected 1321N1 cells were used instead. Amidine compounds 28–
32 showed IC50 < 1 μM while 33 derivatives were less potent (IC50 1–10 μM) [104]. 
Although no in vivo results were presented in this patent, this series of compounds 
were claimed to have therapeutic effects for inflammatory diseases such as IBD, 
ulcerative colitis, Crohn’s disease, arthritis, skin inflammation, pain, itch and cancer.  
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Figure 5. Amidine PAR2 antagonists (28–33) reported by Proximagen Ltd. in 2014. 
 
4.2.5 5-Isoxazolyl-Cha derivatives 
 
A library of GB88 (9) analogues was reported as PAR2 antagonists in patents, 
including piperidines and benzylamide compounds containing 5-isoxazolyl-Cha 
moieties [87, 105]. A series of benzylamide compounds have now published in a 
journal [98]. For example, compounds 13 and 34 (Figures 2 & 6) inhibited calcium 
release induced in HT29 by 2f-LIGRLO-NH2 (1 μM), with IC50 0.5 μM and 0.7 μM, 
respectively. They also inhibited trypsin (100 nM) mediated calcium release with 
micromolar activity. These compounds were found to be very stable in rat plasma 
over 3 h and were more stable than PAR2 peptide agonists (SLIGRL-NH2 and 2f-
LIGRLO-NH2) in rat liver homogenate. Both 13 and 34 attenuated PAR2-induced 
paw oedema when given at 5–10 mg/kg s.c. to rats, with 34 being orally active [98, 
105]. The reported compounds can modulate the functions of PAR2 in inflammatory, 
respiratory, cardiovascular and metabolic diseases; including metabolic syndrome, 
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obesity, type II diabetes, airways/lung inflammation, gastric ulcers, epilepsy, fibrosis, 
diseases of the skin and subcutaneous tissues, diseases of the muscles, bones and 
tendons, diseases of the liver, kidney and genitourinary system [87, 105]. These 
molecules were successfully truncated to give much more potent PAR2 modulators 
such as agonist 5 (EC50 33 nM, Ca2+, hPAR2 transfected CHO cells)[86, 87], although 
the scope for PAR2 antagonists derived from or based on such truncated structures 
has not been disclosed.    
 
4.2.6. Benzothiazine-carboxamide derivatives 
 
In 2015, a group of benzothiazine-carboxamide compounds were reported as PAR2 
antagonists (35–40, Figure 6) with activity at micromolar concentrations [106]. 
Antagonist activity of these compounds against SLIGKV-NH2 (5 μM) was assessed in 
a calcium release assay on HEK cells (35, IC50 1 μM). The phenyl ring on the 
benzothiazine moiety was found to be important for activity, since replacement by a 
thiophene, pyridine, chloro-phenyl or methoxy-phenyl ring reduced potency, while 
displacement of the N-Me with an oxygen atom in 35 abolished antagonist activity. 
On the other hand, the amide could be replaced by thioamide without loss in potency 
(36, IC50 1 μM). The N-Me could also be replaced with a para-halogenated benzyl 
group to maintain or improve antagonist potency (38, IC50 1 μM; 39, IC50 0.8 μM; 40, 
IC50 0.4 μM). These compounds inhibited IL-8 production in human fibroblasts and 
melanin generation in skin pigment of the C57BL/6 Mel-Ab cell lines, indicating the 
possibility for PAR2 antagonists in treating skin inflammation. They might also be 
used as skin-whitening agents [106].  
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Figure 6. 5-Isoxazolyl-Cha (34) and benzothiazine-carboxamide derivatives (35–40) 
as PAR2 antagonists or agonists with sub-micromolar activities.  
 
4.2.7. Imidazopyridazine derivatives 
 
All the PAR2 antagonists (16–40) described previously only possess high 
nanomolar/micromolar/millimolar activity. In 2015, Vertex Pharma reported a series 
of imidazopyridazine derivatives as antagonists for PAR2, although no data was 
provided in support of a direct action on PAR2 [107]. Rather they were reported to 
affect certain activities induced by PAR2 agonists. A decade ago, some 
pyrazolopyrimidine compounds (e.g. compound 41) were reported by Sumitomo 
Pharma to be weakly potent PAR2 antagonists [108]. Modification of this 
pyrazolopyrimidine compound (41) by Vertex Pharma produced imidazopyridazine 
derivatives (42–46) with greater antagonist potency (Figure 7).  
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Figure 7. Imidazolepyridazine compounds reported as potent PAR2 antagonists. 
 
Of 600 imidazopyridazine derivatives synthesized, some of the more potent 
antagonists were evaluated in animal models. It was noted that electron-withdrawing 
groups were preferred at the para-position of phenyl ring, with 4-fluorophenyl giving 
the optimum potency in most cases. In general, substituting the tert-butyl group in 42 
with smaller groups such as dimethyl reduced potency, and with a 5-membered 
aromatic heterocycle, pyridine, or trifluoromethyl group was not well tolerated. 
However, addition of a dimethyl group on the piperazine ring improved potency in 
some cases. Also, the piperazine ring could be coupled to a small aromatic 
heterocycle (imidazole, isoxazole, triazole, pyrazole) without significant loss in 
potency (43, 46). The biological activity of these compounds was assessed in the 
commonly used calcium release assay on HT29 cells. The inhibitory potency of these 
compounds was measured against calcium release induced by SLIGKV-NH2 (8 μM), 
trypsin (3.1 U/mL), thrombin (1 U/mL) or UTP (0.6 μM). Compounds that showed 
promising activities in the calcium assay were tested in rat pharmacokinetic 
experiments, paw oedema, mechanical hypersensitivity and colitis models. The 
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potencies of selected compounds are summarized in Table 3. Compounds 42–46 
displayed promising pharmacokinetic properties, oral bioavailability and were 
effective in reducing carrageenan-induced paw oedema, tryptase-induced nociception, 
and TNBS-induced colitis symptoms in rodent models, suggesting efficacy in 
inflammatory conditions and pain [107].  
 
4.3 Combination inhibitors 
 
A patent has claimed that inhibition of PAR2 can also be achieved by using a 
composition with niacinamide (a vitamin B3 compound), N-undecylenoyl-L-
phenylalanine and a Laminaria Saccharina extract [109]. PAR2 expressed on 
keratinocytes has been shown to regulate pigmentation by transferring melanosomes 
from melanocytes to keratinocytes via phagocytosis. Thus PAR2 activation will result 
in hyperpigmentation and eventually lead to skin inflammation. A composition 
comprises of 5% niacinamide, 1% Sepiwhite (N-undecylenoyl-L-phenylalanine) and 
1% Phlorogine (Laminaria Saccharina extract) inhibited PAR2 activation induced by 
trypsin in β-arrestin luminescence assay. However, the effective concentration of this 
composition was not reported. This patent predicted that the Laminaria Saccharina 
extract was capable of boosting the PAR2 inhibitory effect of niacinamide or 
Sepiwhite and this composition can be applied to human skin surface to reduce 
hyperpigmentation [109].  
 
4.4 Antibodies 
 
In 2014, the global revenue for monoclonal antibody products was estimated to be 
$75 billion and FDA approved 5 new antibody-based drugs [110, 111]. Antibodies that 
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bind to PAR2 might similarly be useful as they can inhibit proteolytic cleavage of the 
TL and subsequent signaling through G proteins or beta-arrestins. Potent and selective 
monoclonal anti-PAR2 antibodies might therefore ameliorate PAR2-mediated 
pathophysiological conditions.  
 
One patent [112] directed at antibodies for PAR2 from Regeneron Pharmaceuticals 
described the generation of fully human monoclonal anti-PAR2 antibodies, using their 
proprietary VelocImmune® mice. These mice were genetically humanized by 
precisely replacing mouse heavy and kappa light chain variable region gene repertoire 
with human germ-line variable sequences [113, 114]. To generate human monoclonal 
anti-PAR2 antibodies, VelocImmune® mice were immunized with the human peptide 
sequence 27GTNRSSKGRSLIGKVDGT45. A series of binding, selectivity and in vitro 
cell assays resulted in monoclonal antibody H4H581P, which inhibited PAR2-
induced NF-κB activation at nM concentrations against trypsin, kallikrein, tryptase 
and factor Xa induced PAR2-mediated NF-κB measured by a luciferase reporter 
assay. Using matrix assisted laser desorption ionization time of flight (MALDI-TOF) 
and alanine scan experiments, H4H581P was shown to bind to Val42 and Asp43 of 
PAR2. In a transgenic mouse model expressing human PAR2, subcutaneous 
administration of H4H581P (25mg/kg) reduced trypsin- or tryptase- induced 
pruritus.REF 
 
Amgen described the generational of monoclonal anti-PAR2 antibodies in two related 
patents [115, 116]. Using the peptide sequence 28TNRSSKGRSLIGVDGTS46 as the 
immunogen, seven monoclonal antibodies were selected and tested for the ability to 
inhibit trypsin-induced calcium mobilization in HCT-116 and PAR2-transfected 
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KNRK cells. The most potent antibody, named 47.7, showed IC50 2 nM in HCT-116 
and 48 nM in PAR2-transfected KNRK cells respectively. In contrast, a commercially 
available PAR2 antibody (SAM11) from Santa Cruz Biotechnology showed only 
slight inhibition (~10%) of trypsin-induced calcium mobilization at 1 µM.  
In separate patents [117, 118], Amgen also described anti-PAR2 antibodies that bind to 
different regions of PAR2. The most potent monoclonal antibody, 1A1 was evaluated 
in two different in vivo carrageenan/kaolin-induced rat knee and paw arthritis models. 
In a knee arthritis model, carrageenan/kaolin and 1A1 were intra-articularly injected 
into each knee and 1A1 showed reduction in knee thickness and visual scoring from 
6–72h after administration. In the paw arthritis model, 1A1 was administered intra-
peritoneally 18h prior to subcutaneous injection of carrageenan into the plantar region 
of the hind paw. Consistent with the arthritis observations, 1A1 reduced paw oedema 
and proinflammatory cytokines (IL-6, IFNγ and oncostatin M) in treated paws as 
compared to untreated arthritic paws. 
Instead of utilizing a PAR2 specific immunogen, Boehringer Ingelheim used antibody 
phage display to screen for Fab fragments that were capable of recognizing the N-
terminus of PAR2 [119]. Further affinity maturation and codon optimization of the 
lead Fab fragment resulted in three high affinity (30–200 pM) PAR2 antibodies that 
bound to the N-terminus of PAR2. These antibodies inhibited trypsin-induced 
intracellular calcium (IC50 0.4–1.8 nM) in several human, mouse and rat cells. In the 
in vivo mouse model of delayed type hypersensitivity, the antibodies dose-
dependently reduced 50% of footpad swelling at 10mg/kg.  
 
4.5 Pepducins 
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Kuliopulos et al disclosed the rational design of pepducins (lipidated peptides) based 
on the first and third intracellular loop sequences, and fifth and sixth intracellular loop 
sequences of PAR2 [60, 120]. Based on the sequence of intracellular loop 3 of PAR2, 8 
different N-palmitoylated peptides were synthesized. The full-length wild-type 
pepducin showed very little antagonist activity against 100 µM SLIGRL, however 
replacement of Arg to Ser, termed P2pal-18S, showed effective antagonism without 
detectable agonist activity. Chemotaxis experiments also demonstrated that P2pal-18S 
selectively blocked trypsin-induced neutrophil migration which was selective to 
PAR2 over PAR1, PAR4 and CXCR2. In the in vivo mouse model of inflammatory 
paw oedema, subcutaneous injection of P2pal-18S (10mg/kg) reduced 50% of paw 
swelling in carrageenan/kaolin-induced paw oedema and 85% in SLIGRL-induced 
oedema. Further histological analysis of mouse footpads showed 60% reduction in the 
infiltrating immune cells as compared to inflamed paws. 
 
5. Conclusions 
 
In the past six years, several new PAR2 agonists and antagonists (peptidic, non-
peptidic, antibody) have been claimed in patents and can evidently modulate the 
functions of PAR2. Some of these modulators were able to activate or inhibit PAR2 
actions in animal models of disease, such as airways inflammation, dermatitis, 
arthritis, colitis, metabolic disorders, pain or cancer. Most PAR2 agonists disclosed 
were peptides, with relatively few nonpeptidic small molecules reported or claimed to 
date. On the other hand, most claimed PAR2 antagonists were small molecules with 
very few peptidic antagonists. Some of these antagonists have been found to inhibit 
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protease-induced PAR2-mediated functions in vivo and might spark further 
development towards clinical trials. Optimizing potency, PAR2-specificity, signaling 
bias for different intracellular activation pathways, and pharmacokinetic properties 
could lead to drug development candidates for validating PAR2 modulation as a 
viable therapeutic approach in the clinic.  
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6. Expert opinion  
 
Evidence from several PAR2 knockout studies has indicated that PAR2 is involved in 
multiple physiological and pathological conditions [2, 5, 21].  Efforts towards 
developing PAR2-selective modulators have revealed some effective strategies for 
realizing pharmacologically active compounds. However, effective and selective 
drugs for modulating PAR2 has been challenging and as yet no small molecule 
modulators have successfully progressed to clinical trials.  
 
There are some significant challenges for bringing PAR2 modulators to the clinic, 
since PAR2 has beneficial properties in normal physiology while being detrimental in 
certain disease settings. PAR2 is now known to be influenced by differential biased 
signaling induced by different proteases and small molecule ligands, and the functions 
of PAR2 appear to be context and cell dependent. Antibodies and protein-based PAR2 
modulators appear less likely to be useful in dissecting out the therapeutic advantages 
predicted to accompany selective or biased modulation of signaling pathways. On the 
otherhand, pathway selective modulation of PAR2 using small molecules appears to 
be more feasible [10, 15] and might be usefully exploited in deriving pharmaceuticals 
that can simultaneously attenuate disease while still conferring protective PAR2-
mediated benefits to cells and tissues. This brings a degree of complexity to the 
evaluation of ligand functions, with an apparent need to examine multiple signaling 
cascades, cell types and in vivo assays, for differential activating or inhibiting 
properties of each ligand and this has slowed the development of PAR2-directed 
modulators. If pathway selective modulation indeed proves to be important, these 
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additional efforts could realize superior PAR2 modulators with greater benefits in 
vivo.  
 
From 2010–2015, a few potent peptidic and non-peptidic PAR2 agonists were 
reported in journals and a patent, with the large lipid peptide 3 being the most potent 
compound (EC50 ~1 nM, Ca2+, 16HBE14o- cells) [85]. However, 3 and small molecule 
agonist 6 have some liabilities including poor solubility. AY77 (5, EC50 33 nM, iCa2+, 
CHO-hPAR2) was recently been reported to be the smallest, most ligand-efficient 
PAR2 agonist that activates the calcium pathway via PAR2 [86, 87]. Not many potent 
PAR2 antagonists have been described recently. Most PAR2 antagonists patented to 
date have been small molecules with high nM or high-micromolar potencies (7–15, 
16–40), while recently claimed PAR2 antagonists (42–46) have yet to be shown to be 
specific for PAR2 [107]. These imidazopyridazine antagonists inhibited both 
SLIGKV- and trypsin-induced calcium release on HT29 cells but not PAR1 induced 
activities. They had oral bioavailability (F% >50) and showed some anti-
inflammatory activity in rodents. No evidence however has been reported yet for their 
direct binding to, or action through PAR2, or for differential effects on different 
PAR2 signaling pathways.  
 
While some progress has been made in profiling the therapeutic potential of PAR2 
antagonists, fewer studies have examined the therapeutic potential of PAR2 agonists 
and further research is needed to explore this potential. There has been some 
controversy about the roles of PAR2 being pro- or anti-inflammatory. Some reports 
have suggested that PAR2 activation is protective in the airways [40, 41, 121] and other 
tissues, which may be associated with G-protein dependent signaling [46]. Pro-
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inflammatory responses caused by PAR2 activation have alternatively been associated 
with β-arrestin dependent signaling [46]. A biased PAR2 agonist that only signals via 
certain G-proteins or only via β-arrestins would be a useful probe for understanding 
context-dependent PAR2 activation in both normal physiology and disease settings.  
 
Not many potent and pathway-selective ligands have been developed for PAR2 to 
date. Most PAR2 ligands reported in this review have only been evaluated in the 
PAR2-induced calcium pathway and only in one or a few cell types. There is a need 
to more widely investigate PAR2 ligand profiles in multiple PAR2-associated 
signaling pathways, multiple cell lines and multiple disease models to better 
understand the pharmacology of PAR2 modulation. A worthy goal appears to be not 
only to develop PAR2-selective and potent modulators with few off-target effects, but 
also to develop pathway-selective ligands for PAR2 to minimize on-target but off-
pathway side effects. Thus drug development for PAR2 may not only require on-
target selectivity, but also on-pathway selectivity, in order to realize the full potential 
of this receptor in modulating particular diseases.  
 
In conclusion, the discovery of PAR2 modulators as new therapeutic agents has 
presented a number of new challenges for GPCR drug development. There is no 
endogenous agonist ligand to use as a starting point for drug development. The 
finding of ligand-induced biased signaling for both protease agonists and small 
molecule ligands presents further challenges as well as new opportunities. In the past 
six years, not many potent PAR2 ligands were reported in either patents or the 
scientific literature. However, given the promise of PAR2 and the new findings of 
biased signaling ligands, there appear to be exciting opportunities on the horizon in 
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this field. It seems likely that PAR2 modulators will progress into the clinic over the 
next few years for several disease conditions.  
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Article highlight box  
 
• PAR2 is associated with inflammatory, cardiovascular, gastrointestinal, 
respiratory and metabolic diseases, highlighting it as a potentially valuable 
therapeutic target. It is also associated with pain, itch, wound healing and 
cancer metastasis. 
• Patents reporting new PAR2 agonists, antagonists, antibodies and pepducins 
from 2010–2015 are examined. 
• Structure-activity relationships and biological activities of PAR2 modulators 
in vitro and in vivo as described in patents are reported.  
• PAR2 modulators have been found to be beneficial for treating animal models 
of disease.  
• Biased ligands for PAR2 show promise for modulating different signaling 
pathways that may be linked to different diseased states.  
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Table 1. Summary of PAR2-induced or -related disease models and therapeutic 
effects of PAR2 antagonism/knockout (KO). 
Disease 
model 
PAR2 
agonist(s) 
PAR2 
antagonism 
Therapeutic 
effects 
References 
Mouse model of 
arthritis induced 
by destabilisation 
of medial 
meniscus 
N.A PAR2 
antibody 
(SAM11), 
PAR2 KO 
Inhibited cartilage 
erosion, swelling and 
arthritis pathology 
[55, 56] 
Synovial 
fibroblasts 
isolated from 
patient with 
rheumatoid 
arthritis 
SLIGRL-NH2 ENMD-1068, 
PAR2 siRNA 
Inhibited invasion 
and proliferation of 
synovial fibroblasts 
and TNF secretion 
[57] 
Mouse model of 
oxazolone-
induced 
dermatitis 
N.A PAR2 KO Reduced oedema and 
inflammatory cells 
infiltration 
[58] 
Rat model of paw 
oedema 
2f-LIGRLO-NH2  GB88 Prevented collagen 
loss, mast cell 
degranulation and 
macrophages 
accumulation  
[59] 
Mouse model of 
paw oedema 
Mast cell tryptase 
SLIGRL-NH2 
P2pal-18S Inhibited edema and 
myeloperoxidase 
activity  
[60] 
Mouse model of 
DSS-induced 
colonic 
inflammation 
N.A PAR2 KO Reduced edema, 
fecal blood and 
bowel thickness 
[61] 
Human colonic 
epithelial cells 
(HT29) 
2f-LIGRLO-NH2 
SLIGKV-NH2 
PAR2 siRNA Reduced cytokines-
induced apoptosis 
[62] 
Rat model of 
colonic 
inflammation 
SLIGRL-NH2 GB88 Inhibited mucin 
depletion and colon 
wall thickness 
[63] 
Mouse model of 
ovalbumin-
induced airway 
inflammation 
N.A PAR2 KO Inhibited eosinophil 
infiltration and 
hyperreactivity 
[64] 
Mouse model of 
asthma 
German 
cockroach feces 
extracts 
PAR2 KO Reduced airway 
inflammation and 
immune cells 
recruitment 
[65] 
Mouse model of 
asthma 
House dust mite 
extracts 
PAR2 KO Reduced airway 
inflammation and 
eosinophil 
accumulation 
[66] 
Mouse model of 
cancer 
nociception 
Trypsin PAR2 KO  Inhibited cancer-
induced allodynia 
[67] 
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Mouse model of 
hyperalgesia 
SLIGRL-NH2 
Trypsin 
Tryptase 
PAR2 KO Reduced thermal and 
mechanical 
hyperalgesia 
[68] 
Mouse model of 
hyperalgesia 
Neutrophil 
elastase 
PAR2 KO Reduced edema and 
mechanical 
hyperalgesia 
[69] 
Mouse model of 
bone cancer-
induced 
hyperalgesia 
N.A FSLLRY-NH2 
PAR2 KO 
Reduced mechanical 
allodynia and 
thermal hyperalgesia 
[70] 
Mouse model of 
pancreatitis-
induced 
hyperalgesia 
2f-LIGRLO-NH2 PAR2 KO Agonist reduced 
hyperalgesia and 
allodynia in WT 
mice 
[71] 
Mouse model of 
diet-induced 
metabolic 
dysfunction 
N.A PAR2 KO 
 
Prevented weight 
gain, insulin 
resistance and 
inflammation 
[44] 
Rat model of 
diet-induced 
metabolic 
dysfunction 
NA GB88 Prevented weight 
gain, insulin 
resistance and 
inflammation 
[45] 
Mouse model of 
retinal 
angiogenesis 
SLIGRL-NH2 PAR2 KO Agonist improved 
retinal 
vascularisation and 
angiogenesis in WT 
mice 
[72] 
Mouse model of 
mammary 
tumour 
N.A PAR2 KO Delayed 
development and 
metastasis of tumor 
[73] 
Mouse model of 
mammary 
tumour 
N.A PAR2 KO 
 
Delayed 
development and 
metastasis of tumor 
[74] 
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Table 2. Summary of the inhibitory activities of small molecule PAR2 antagonists (reported in patents 2010–2015) against different PAR2 
agonists, assessed in an intracellular calcium release assay.  
Compd Patent number Organization Derivatives Cell line IC50 
(μM) 
Agonist used Possible therapeutic 
applications 
16 KR2010038919 NeoPharm Co. 
Ltd. 
Piperazine/piperidine 
compounds 
HCT-15 
 
~1200 
SLIGKV (2.5 μM) 
Atopic dermatitis 
21–24 KR2011130259 NeoPharm Co. 
Ltd. 
Quinazoline compounds 9–34 Cardiovascular, 
gastrointestinal, digestive tract 
diseases, cirrhosis, atopic 
dermatitis, asthma, etc 
25–27 WO2012026765 
WO2012026766 
NeoPharm Co. 
Ltd. 
Benzoimidazole 
compounds 
75–243 Skin diseases 
17–20 WO2012101453 Proximagen 
Ltd. 
Piperidine/Piperazine 
urea compounds 
Human 
PAR2 
transfected 
1231N1 
< 5 
Trypsin (EC50 
conc.) 
Multiple inflammatory 
diseases and cancer 
28–33 WO2014020350 
WO2014020351 
Proximagen 
Ltd. 
Amidine compounds Rat or mouse 
PAR2 
transfected 
1231N1 
< 1 
13, 34 WO2013013273 
US20150038402 
The University 
of Queensland 
5-Isoxazolyl-Cha 
compounds  
 
HT29 0.4–4.0 2f-LIGRLO-NH2 
(1.0 μM), trypsin 
(0.1 μM) 
Inflammation, metabolic 
syndrome, obesity, type II 
diabetes, fibrosis, 
cardiovascular diseases, etc. 
35–40 KR2015044675 AmorePacific 
Corp. 
Benzothiazine-
carboxamide 
compounds 
HEK 0.4–1.0 SLIGKV (5 μM) Skin inflammation 
41–46 WO2015048245 Vertex Pharm. Imidazopyridazine 
compounds 
HT29 0.001–
0.01 
SLIGKV (8 μM), 
trypsin (3.1 U/mL) 
Inflammation and pain 
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Table 3. Pharmacological properties of selected imidazopyridazine derivatives [107]. 
 42 43 44 45 46 
IC50 (nM, Ca2+, 
HT29) vs SLIGKV 1.4 0.7 7.5 2.2 0.5 
IC50 (nM, Ca2+, 
HT29) vs Trypsin 2.3 0.9 10.2 2.0 0.8 
IC50 (nM, Ca2+, 
HT29) vs 
Thrombin & UTP 
>400 >400 >3500 >1000 >1000 
T1/2 (h)* 57 4 5 78 7.0 
Clp (mL/min/kg)* 0.7 10.9 4.8 1.1 3.4 
Vss* 3.2 3.3 1.6 6.8 1.6 
F %* 66 55 70 76 62 
Inhibition of 
carrageenan-
induced paw 
oedema* 
50% 
(6mg/kg) 
55% 
(5mg/kg) 
51% 
(6mg/kg) 
19% 
(20mg/k
g) 
50% 
(10mg/kg) 
Inhibition of 
tryptase-induced 
nociception* 
40% 
(10mg/kg) 
52% 
(5mg/kg) 
43% 
(6mg/kg) N.A. 
23% 
(10mg/kg) 
Inhibition of 
TNBS-induced 
colitis** 
21% 
(15mg/kg) N.A. N.A. N.A. 
24% 
(15mg/kg) 
Vss Volume of distribution at steady-state; N.A. not available 
* Experiments performed in rats; ** in mice 
 
 	
